NCT00671372View on ClinicalTrials.gov

A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Colorectal Cancer
Interventions
DRUG

FOLFIRI regimen

Intravenous repeating dose

DRUG

bevacizumab

Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)

DRUG

cetuximab

Intravenous repeating dose

DRUG

dulanermin

Intravenous repeating dose

DRUG

irinotecan

Intravenous repeating dose

Trial Locations (10)

14263

Buffalo

17033

Hershey

27710

Durham

33916

Fort Myers

37203

Nashville

60426

Harvey

90095

Los Angeles

92374

Redlands

94115

San Francisco

98405

Tacoma

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT00671372 - A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter